ALASKA MEDICAID
Prior Authorization Criteria

Jascayd®
(nerandomilast)

FDA INDICATIONS AND USAGE[1]

Jascayd® is a is a phosphodiesterase 4 (PDE4) inhibitor indicated for:

- The treatment of idiopathic pulmonary fibrosis in adult patients.
- The treatment of progressive pulmonary fibrosis in adult patients.

APPROVAL CRITERIA[1,2,3]

1. Patient meets FDA labeled age **AND**;
2. Prescribed by or in consultation with a pulmonologist **AND**;
3. Other known causes of interstitial lung disease have been ruled out (e.g. environmental exposure, drug toxicity, connective tissue disease, etc.) **AND;**
4. Documented pulmonary function test within the past 60 days reflecting Forced Vital Capacity (FVC) ≥45% of predicted **AND;**
5. Patient baseline carbon monoxide diffusing capacity (DLCO, corrected for hemoglobin) ≥25% of predicted **AND;**
6. Patient has the diagnosis of Idiopathic Pulmonary Fibrosis (IPF) confirmed by lung biopsy OR high-resolution computed tomography **OR;**
7. Patient has the diagnosis of Progressive Pulmonary Fibrosis (PPF) consistent with current, established guidelines.

DENIAL CRITERIA [1]

1. Failure to meet approval criteria **OR**;
2. Jascayd® is being used in combination with a moderate or strong CYP3A inducer

CAUTIONS[1]

- Dose modification may be necessary when used concomitantly with strong CYP3A inhibitors.
- Diarrhea was the most commonly reported side effect

DURATION OF APPROVAL

- Initial Approval: up to 3 months
- Reauthorization Approval: up to one year

QUANTITY LIMIT

- 60 tablets per 30 days

REFERENCES / FOOTNOTES:

1. Jascayd (nerandomilast) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim.; December 2025
2. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2193-2202..
3. Maher T, Assassi S, Azuma A, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med 2025; 392(22): 2203-2214